Business
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-relat...
About this update from Bolt Metals Corp.
[{"type":"text","content":"Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025\n\n\n\n\n BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events\n \n\n\n\n BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines\n \n\n\n\n BDC-3042 showed signs of anti-tumor activity, including an unconfirmed partial response, stable disease ≥ 12 weeks in 3/3 non-small cell lung cancer patients and in 2/3 patients at the highest dose\n \n\n\n\n Bolt is running a partnering process to advance development of BDC-3042\n \n\n\n REDWOOD CITY, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced results from its Phase 1 dose-escalation clinical study of BDC-3042 at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.\n \n\n “We are excited about the potential of BDC-3042 to help patients with cancer. This initial dose-escalation study demonstrated a favorable safety profile, dose-dependent biologic activity, and monotherapy anti-tumor activity,” said Willie Quinn, Chief Executive Officer. “BDC-3042 deserves rapid development, especially given its enormous commercial potential. We are launching a process to find a partner with the resources to accelerate development and optimize commercialization.”\n \n\n BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). Dectin-2 is a C-type lectin receptor best known for its role in pathogen recognition and induction of protective immune responses against fungi and other microbes. This single-agent, dose-escalation Phase 1 clinical study is evaluating BDC-3042 in patients with metastatic or unresectable triple-negative breast cancer (TNBC), clear cell renal cell carcinoma (ccRCC), colorectal cancer (CRC), melanoma, non-small cell lung cancer (NSCLC), and ovarian cancer.\n \n\n\n Key Clinical Study Findings:\n \n\n\n Seventeen patients with six different tumor types and a median of four prior lines of ther...